C.R. Bard, Inc. (BCR) Shares Sold by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI lowered its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 1.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,743 shares of the medical instruments supplier’s stock after selling 452 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in C.R. Bard were worth $10,494,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Monroe Bank & Trust MI increased its stake in shares of C.R. Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of C.R. Bard by 70.4% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of C.R. Bard by 2.8% during the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after acquiring an additional 14 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of C.R. Bard during the 2nd quarter valued at about $192,000. Finally, Choate Investment Advisors purchased a new stake in shares of C.R. Bard during the 2nd quarter worth about $201,000. 79.21% of the stock is owned by institutional investors.

BCR has been the subject of a number of research reports. Barclays boosted their target price on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a report on Monday, November 6th. Jefferies Group reiterated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a report on Thursday, September 14th. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Cowen reiterated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a report on Friday, November 3rd. Finally, ValuEngine cut C.R. Bard from a “buy” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a strong buy rating to the company. C.R. Bard currently has an average rating of “Hold” and a consensus price target of $303.50.

In other C.R. Bard news, Vice Chairman John H. Weiland sold 33,435 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $333.31, for a total value of $11,144,219.85. Following the completion of the transaction, the insider now owns 76,331 shares in the company, valued at approximately $25,441,885.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Frank Lupisella, Jr. sold 9,173 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total value of $2,981,225.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 191,593 shares of company stock valued at $62,655,513. 0.80% of the stock is owned by company insiders.

Shares of C.R. Bard, Inc. (BCR) opened at $332.55 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. C.R. Bard, Inc. has a fifty-two week low of $206.71 and a fifty-two week high of $337.73. The stock has a market capitalization of $24,496.21, a PE ratio of 29.02, a PEG ratio of 2.57 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.64 EPS. research analysts expect that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio is presently 13.70%.

ILLEGAL ACTIVITY NOTICE: “C.R. Bard, Inc. (BCR) Shares Sold by Citizens Financial Group Inc. RI” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/05/c-r-bard-inc-bcr-shares-sold-by-citizens-financial-group-inc-ri.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply